Pharmaceutical

Pharmanovia signs license agreement for Lindis Biotech’s catumaxomab

Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab for malignant ascites.

Nov 21, 2024 - 06:00
Pharmanovia signs license agreement for Lindis Biotech’s catumaxomab
Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab for malignant ascites.
Read the original article

Tags:

Previous Article

Parkinson’s disease cases to reach 3.15 million in 7MM by 2033

Next Article

Wes Streeting says patients should view data sharing ‘the same as taxes’

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Direct-to-patient communication: Bridging the gap in medication adherence

Direct-to-patient communication: Bridging the gap in me...

Sep 28, 2024

STAT+: UnitedHealth is on a buying spree of outpatient surgery centers

STAT+: UnitedHealth is on a buying spree of outpatient ...

Mar 12, 2024

STAT+: Maryland pushes first-of-its-kind bill to promote alternatives to animals in biomedical research

STAT+: Maryland pushes first-of-its-kind bill to promot...

Apr 25, 2023